Merck has bought Massachusetts based FloDesign Sonics, developer of a unique acoustic cell processing platform for the industrialization of cell and gene therapy manufacturing, that allows enhanced cell washing and concentration for manufacturing cell therapies. This makes Merck the first company to make acoustic technology available for cell therapy manufacturing, and reinforces the company’s ability alongside pharmaceutical manufacturers to advance cell-based therapies to patients.
Stanley Kowalski III, co-founder, chairman and CEO of FloDesign Sonics, said: “Merck is the best home for FloDesign Sonics, our acoustic cell processing technology and our employees. The opportunity for FloDesign Sonics to become part of a world class 351-year-old science and technology company is very rewarding.”
“Merck acquires FloDesign Sonics“
Udit Batra, Merck Executive Board member and CEO Life Science, said: “Chimeric antigen receptor T cell therapies, or CAR-T for short, employs the body’s own immune systems to fight cancer by turning T cells into targeted therapeutics. This revolutionary cancer treatment is challenging and complex, with the process often taking up to a month. Our acquisition of FloDesign Sonics will industrialize the manufacturing of autologous cell therapy, allowing these types of potentially life-saving treatments to reach more patients, faster.”